The pharmaceutical community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s demonstrating significant potential in clinical trials for treating obesity. Unlike some existing weight loss solutions, retatrutide appears to offer a greater substantial reduction in body mass and benefit metabolic health, pa… Read More